Document Detail


Parathyroid hormone treatment for osteoporosis.
MedLine Citation:
PMID:  18971677     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE OF REVIEW: There has recently been a dramatic expansion of clinical investigation of parathyroid hormone (PTH). There are no other anabolic agents on the horizon at the current time but clearly there are a large number of questions that remain about this powerful agent for osteoporosis. RECENT FINDINGS: The present study reviews clinical trials using PTH alone and in combination and sequence with antiresorptive agents in postmenopausal women and briefly overviews trials in glucocorticoid-induced osteoporosis in men. PTH will be referred to as teriparatide when it is the recombinant human PTH(1-34) fragment produced by Lilly (Indianapolis, Indiana, USA) or the human PTH(1-34) produced by biochemical synthetic methods (Bachem, California, USA); and PTH(1-84) as the intact human recombinant molecule developed by NPS Pharmaceuticals (Salt Lake City, Utah, USA). PTH without other designation denotes either of the compounds. SUMMARY: Because PTH improves microarchitecture, macroarchitecture and mass of bone, it might produce better long-term protection against fracture, when given first and followed by antiresorptive therapy, compared with antiresorptive agents alone. Results of studies on combination therapy must distinguish previously untreated vs. previously treated individuals. PTH should be considered in women with persistent osteoporosis on established bisphosphonates or raloxifene, in which adding PTH might produce better results than switching to PTH. There are still many unanswered questions concerning PTH therapy, one of the most important being the optimal regimen.
Authors:
Felicia Cosman
Related Documents :
20132057 - Oncolytic (replication-competent) adenoviruses as anticancer agents.
17458367 - Defining spirituality and giving meaning to occupation: the perspective of community-dw...
20103477 - Future approaches in periodontal regeneration: gene therapy, stem cells, and rna interf...
12476067 - Gene therapy in the post-gelsinger era.
23192167 - Surgery and anesthesia capacity-building in resource-poor settings: description of an o...
16534337 - Guidelines on the ethics of clinical research in anaesthesia.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current opinion in endocrinology, diabetes, and obesity     Volume:  15     ISSN:  1752-2978     ISO Abbreviation:  -     Publication Date:  2008 Dec 
Date Detail:
Created Date:  2008-10-30     Completed Date:  2008-12-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101308636     Medline TA:  Curr Opin Endocrinol Diabetes Obes     Country:  England    
Other Details:
Languages:  eng     Pagination:  495-501     Citation Subset:  IM    
Affiliation:
Columbia College of Physicians and Surgeons, Columbia University, New York, New York, USA. cosmanf@helenhayeshosp.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anabolic Agents / administration & dosage
Bone Density Conservation Agents / therapeutic use
Diphosphonates / administration & dosage
Drug Therapy, Combination
Female
Hormone Replacement Therapy / methods*
Humans
Male
Osteoporosis / drug therapy*
Parathyroid Hormone / administration & dosage*
Raloxifene / administration & dosage
Randomized Controlled Trials as Topic
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anabolic Agents; 0/Bone Density Conservation Agents; 0/Diphosphonates; 0/PTH protein, human; 0/Parathyroid Hormone; 84449-90-1/Raloxifene

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Assessment of vitamin D status and definition of a normal circulating range of 25-hydroxyvitamin D.
Next Document:  Osteoporosis: how long should we treat?